DATA The mode of action of the antifungal agent CPO

Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
MOLECULE
DATA
The mode of action of the antifungal agent CPO
(6-cyclohexyl-1hydroxy-4-methyl-2(1H)-pyridone) results in
intracellular depletion of essential substrates
and/or ions resulting growth inhibition or fungal
death [4/9]. This class of antifungal agents,
hydroxypyridones, are considered G1/S phase
1 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
initiation blockers [4]. A relationship between
the mode of action and adherence mechanism
and an antiinflamatory and antiallergenic effect
has been established for ciclopiroxolamine
(CPO). The hydroxypyridones are active
against yeasts, dermatophytes and filamentous
fungi, and CPO has been evaluated previously
by different methods and compared with other
topical antifungal drugs. CPO has been used in
the management of genital candidiasis or
mycotic vulvovaginitis, pityriasis versicolor and
other skin mycoses as a cream or lacquer
formulation.
CPO has good in vitro antifungal activity
compared with azole derivative antifungal drugs
used for the management of superficial
mycoses. Such activity has been previously
described using unstandardized microdilution
and agar dilution methods rather than the
commercial agar diffusion method,
NeoSensitabs†. CPO appeared active in vitro
against C. albicans, C. glabrata, C. parapsilosis
2 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
and C. tropicalis as has been shown in previous
studies with other imidazole derivatives used in
the topical management of genital candidosis.
Results using a microdilution method showed
Candida to be susceptible to 0.98/3.9 mg/l CPO
in contrast with those of Hernandez-Molina et
al. who found the MIC90 for CPO to be 8
mg/ml. Resistance levels for miconazole,
econazole and ketoconazole are similar to
those reported in other studies.
REFERENCES
Carrillo-Muñoz AJ, S. Brio, R. Alonso,
O. del Valle, P. Santos, G. Quindos.
Ciclopiroxolamine: in vitro antifungal
activity against clinical yeast isolates.
International Journal of Antimicrobial
Agents 20 (2002) 375/379
3 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
Fromtling RA. Overview of medically
important azole derivatives. Clin
Microbiol Rev 1988;1:187/217.
Carrillo-Muñoz AJ, Pema´n J,
Gobernado M. Nuevos antifúngicos.
Rev Esp Quimioter 1999;12:181/204.
Carrillo-Muñoz AJ, Bró S, Quindos G.
Una nueva generación de fármacos
antifúngicos. Rev Iberoam Micol
2001;18:2/5.
4 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
Iwata K, Yamaguchi H. Studies on the
mechanism of antifungal action of
ciclopiroxolamine/inhibition of
transmembrane transport
of amino acid, K/ and phosphate in
Candida albicans cells. Arzn Forch
1981;31:1323/7.
Abrams BB, Hanel H, Hoehler T.
Ciclopirox olamine: a hydroxypyridone
antifungal agent. Clin Dermatol
1991;9:471/7.
Korting HC, Grundmann-Kollmann M.
5 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
The hydroxypyridones: a class of
antimycotics of its own. Mycoses
1997;40:243/7.
Braga PC, Piatti G, Conti E, Vignali F.
Effects of subinhibitory concentrations
of ciclopirox in the adherence of
Candida albicans to human bucal and
vaginal cells. Arzn Forch
1992;42:1368/71.
Torres JM. Ciclopiroxolamina. Un
Nuevo antifungico tópico, uso
terapeutico. Drugs Today
6 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
1989;25:1/17.
Harada I, Mitsui K, Uchida K,
Yamaguchi H. In vitro antifungal
activity of rilopirox, a new
hydroxypyridone antimycotic agent.
Jpn J Antibiot 1997;50:195/9.
Rai MK, Upadhyay SK, Agrawal SC.
In vitro evaluation of three topical
antimycotics against ring-worm fungi
singly and in combination. Hind
Antibiot Bull 1992;34:104/7.
7 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
Hernandez-Molina JM, Llosa J,
Martinez-Brocal A, de la Rosa L.
Sensitivity of yeasts of the genus
Candida to new antifungal agents.
Enferm Infect Microbiol Clin
1991;9:405/8.
Hanel H, Raether W, Dittmar W.
Evaluation of fungicidal action in vitro
and a skin model considering the
influence of penetration kinetic
various standard antimycotics. Ann
New York Acad Sci 1988;544:329/37.
8 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
Yamaguchi H, Uchida K, Hiratani T, et
al. In vitro activity of ME1401, a new
antifungal agent. Antimicrob Angents
Chemother 1986;30:705/12.
Oliveri S, Cammarata E, Cappello G,
Di Prima T, Fallica L, Panizza E.
Ciclopiroxolamine: clinical and
microbiological considerations.
Preliminary data. Chimioterapia
1986;5:23/5.
Garcıa-Figueroa RG, Sauceda L,
Ramı´rez-Palacios D, Cruz-Talonia F,
9 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
Romero-Cabello R. Efectiveness and
safety of ciclopiroxolamine 1% vaginal
cream versus terconazole 0.8%
vaginal cream the treatment of genital
candidiasis. Ginecol Obstet Mex
2000;68:154/9.
Giannoni M, Pollastro M, Jacobellis
M. A clinical study of
ciclopyroxolamine versus clotrimazole
in the treatment of mycotic
vulvovaginitis. Minerva Med
1990;81:555/9.
10 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
Corte M, Jung K, Linker U, Martini H,
Sapp-Boncelet I, Schulz M. Topical
application of a 0.1%
ciclopiroxolamine solution for the
treatment of pityriasis versicolor.
Mycoses 1989;32:200/3.
Lecha-Carralero V, Martıinez-Tomas
C. Experience in the treatment of skin
mycoses with ciclopiroxolamine. Med
Cutanea Ibero Lat Am 1989;17:35/8.
Jue SG, Dawson GW, Brodgen RN.
Ciclopiroxolamine 1% cream. A
11 / 12
Ciclopiroxolamina
Escrito por Administrator
Miércoles, 25 de Marzo de 2009 10:50 - Actualizado Sábado, 04 de Abril de 2009 08:52
preliminary review of antimicrobial
activity and therapeutic use. Drugs
1985;29:330/41.
12 / 12